MISSISSAUGA, ON, Oct. 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the third quarter of 2025 after the market close on Thursday, November 6, 2025. The Company will also hold a conference call on Friday, November 7, 2025 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE: | Friday, November 7, 2025 |
TIME: | 8:30 a.m. ET |
DIAL-IN NUMBER: | 416-945-7677 or 888-699-1199 |
REPLAY: | 289-819-1450 or 888-660-6345 Code: 24367# |
Expires: November 14, 2025 | |
WEBCAST: |
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
| Last Trade: | C$15.10 |
| Daily Volume: | 0 |
| Market Cap: | C$383.090M |
November 06, 2025 August 07, 2025 May 08, 2025 April 29, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
